UY27679A1 - Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea. - Google Patents

Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea.

Info

Publication number
UY27679A1
UY27679A1 UY27679A UY27679A UY27679A1 UY 27679 A1 UY27679 A1 UY 27679A1 UY 27679 A UY27679 A UY 27679A UY 27679 A UY27679 A UY 27679A UY 27679 A1 UY27679 A1 UY 27679A1
Authority
UY
Uruguay
Prior art keywords
ambroxol
oral
treatment
cavity
faringian
Prior art date
Application number
UY27679A
Other languages
English (en)
Spanish (es)
Inventor
Esperester Anke
Pschorn Uwe
Vix Jean-Michelj
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27740434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27679(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27679A1 publication Critical patent/UY27679A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY27679A 2002-02-27 2003-02-25 Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea. UY27679A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208313A DE10208313A1 (de) 2002-02-27 2002-02-27 Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum

Publications (1)

Publication Number Publication Date
UY27679A1 true UY27679A1 (es) 2003-09-30

Family

ID=27740434

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27679A UY27679A1 (es) 2002-02-27 2003-02-25 Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea.

Country Status (21)

Country Link
EP (1) EP1480626A1 (de)
JP (1) JP2005518435A (de)
KR (1) KR20040084944A (de)
CN (1) CN1638749A (de)
AR (1) AR038698A1 (de)
AU (1) AU2003210345B2 (de)
BR (1) BR0308038A (de)
CA (1) CA2477105A1 (de)
DE (1) DE10208313A1 (de)
EC (1) ECSP045242A (de)
IS (1) IS7417A (de)
MX (1) MXPA04008220A (de)
MY (1) MY144781A (de)
PE (1) PE20030830A1 (de)
PL (1) PL371584A1 (de)
RU (1) RU2311176C2 (de)
TW (1) TW200306804A (de)
UA (1) UA86741C2 (de)
UY (1) UY27679A1 (de)
WO (1) WO2003072094A1 (de)
ZA (1) ZA200405635B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10332486A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung akuter Schmerzen
JP2005120063A (ja) * 2003-10-14 2005-05-12 Boehringer Ingelheim Pharma Gmbh & Co Kg 咽頭における炎症の治療のためのアンブロキソール
ITMI20032462A1 (it) * 2003-12-16 2005-06-17 Advance Holdings Ltd Metodo per preparare una caramella contenente ambroxolo e la caramella cosi' ottenuta
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
JP2007084471A (ja) * 2005-09-21 2007-04-05 Sunstar Inc 口腔用組成物および口腔用製品の選択方法
EP2015761A4 (de) * 2006-03-29 2009-07-29 Naveh Pharma 1996 Ltd Verfahren und zusammensetzung zur behandlung von halsentzündung
JP5765934B2 (ja) * 2009-12-28 2015-08-19 サンスター株式会社 口腔用組成物
JP6171683B2 (ja) * 2012-08-03 2017-08-02 大正製薬株式会社 固形製剤
CN105769908B (zh) * 2016-05-06 2019-03-01 湖北凤凰白云山药业有限公司 一种化痰止咳的药物及其制备方法
WO2018089797A1 (en) 2016-11-14 2018-05-17 Mingwu Wang Formulations for the treatment of ocular surface diseases and related methods
CN106727621A (zh) * 2016-11-22 2017-05-31 郑州仁宏医药科技有限公司 一种治疗牙痛的西药散剂
JP6844394B2 (ja) * 2017-04-14 2021-03-17 大正製薬株式会社 固形組成物
EP3415143A1 (de) 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexin zur behandlung von schmerz

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138020B1 (de) * 1983-09-17 1992-06-03 Dr. Karl Thomae GmbH Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat
DE3445226A1 (de) * 1983-12-14 1985-08-01 Reifenrath, Rainer Richard Otto, Dr.med., 7920 Heidenheim Pharmazeutisches erzeugnis zur behandlung und prophylaxe von infektionen sowie von husten und obstruktiven atemwegserkrankungen
US5122540A (en) * 1986-02-28 1992-06-16 W. Keith R. Watson Method and composition for treating warts and throat soreness with DMSO and citric acid
DE4415553A1 (de) * 1994-05-03 1995-11-09 Behringwerke Ag Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
WO1997041832A1 (fr) * 1996-05-02 1997-11-13 Taisho Pharmaceutical Co., Ltd. Suspension de medicament acide difficilement soluble dans l'eau
DE19933148A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物
DE20102817U1 (de) * 2000-02-23 2001-06-07 Bolder Arzneimittel GmbH, 50968 Köln Lutsch- und Kaupastillen mit Cyclodextrin
US6391886B1 (en) * 2000-12-04 2002-05-21 The Procter & Gamble Company Oral compositions having improved consumer aesthetics

Also Published As

Publication number Publication date
RU2311176C2 (ru) 2007-11-27
AU2003210345B2 (en) 2009-01-29
AR038698A1 (es) 2005-01-26
EP1480626A1 (de) 2004-12-01
JP2005518435A (ja) 2005-06-23
CA2477105A1 (en) 2003-09-04
MY144781A (en) 2011-11-15
TW200306804A (en) 2003-12-01
PE20030830A1 (es) 2003-10-31
WO2003072094A1 (de) 2003-09-04
AU2003210345A1 (en) 2003-09-09
MXPA04008220A (es) 2004-11-26
PL371584A1 (en) 2005-06-27
RU2004129284A (ru) 2005-06-10
UA86741C2 (ru) 2009-05-25
CN1638749A (zh) 2005-07-13
DE10208313A1 (de) 2003-09-11
BR0308038A (pt) 2004-12-28
IS7417A (is) 2004-08-19
KR20040084944A (ko) 2004-10-06
ZA200405635B (en) 2005-05-31
ECSP045242A (es) 2004-09-28

Similar Documents

Publication Publication Date Title
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
UY27679A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea.
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
FR2878159B1 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
ITTO20040621A1 (it) Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
ECSP077843A (es) Tratamiento o prevención del prurito
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
PA8800401A1 (es) Productos quimioterapeuticos cristalinos
PA8800601A1 (es) Productos quimioterapeuticos cristalinos
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
BR0309808A (pt) Combinação para o tratamento de distúrbios das vias aéreas
AR077451A1 (es) Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
ATE439354T1 (de) Pharmazeutische salze von reboxetin

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126